Bryan J Taylor1, Eric M Snyder2, Maile L Richert3, Courtney M Wheatley3, Steven C Chase4, Lyle J Olson3, Bruce D Johnson3. 1. Faculty of Biological Sciences, School of Biomedical Sciences, University of Leeds, Leeds, UK; Division of Cardiovascular Diseases, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA. Electronic address: b.j.taylor@leeds.ac.uk. 2. School of Kinesiology, University of Minnesota, Minneapolis, Minnesota, USA. 3. Division of Cardiovascular Diseases, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA. 4. Division of Cardiovascular Diseases, Mayo Graduate School, Mayo Clinic, Rochester, Minnesota, USA.
Abstract
BACKGROUND: The purpose of this study was to determine: (1) whether stable heart failure patients with reduced ejection fraction (HFrEF) have elevated extravascular lung water (EVLW) when compared with healthy control subjects; and (2) the effect of acute β2-adrenergic receptor (β2AR) agonist inhalation on lung fluid balance. METHODS: Twenty-two stable HFrEF patients and 18 age- and gender-matched healthy subjects were studied. Lung diffusing capacity for carbon monoxide (DLCO), alveolar-capillary membrane conductance (DmCO), pulmonary capillary blood volume (Vc) (via re-breathe) and lung tissue volume (Vtis) (via computed tomography) were assessed before and within 30 minutes after administration of nebulized albuterol. EVLW was derived as Vtis - Vc. RESULTS: Before administration of albuterol, Vtis and EVLW were higher in HFrEF vs control (998 ± 200 vs 884 ± 123 ml, p = 0.041; and 943 ± 202 vs 802 ± 133 ml, p = 0.015, respectively). Albuterol decreased Vtis and EVLW in HFrEF patients (-4.6 ± 7.8%, p = 0.010; -4.6 ± 8.8%, p = 0.018) and control subjects (-2.8 ± 4.9%, p = 0.029; -3.0 ± 5.7%, p = 0.045). There was an inverse relationship between pre-albuterol values and pre- to post-albuterol change for EVLW (r2 = -0.264, p = 0.015) and DmCO (r2 = -0.343, p = 0.004) in HFrEF only. CONCLUSION: Lung fluid is elevated in stable HFrEF patients relative to healthy subjects. Stimulation of β2ARs may cause fluid removal in HFrEF, especially in patients with greater evidence of increased lung water at baseline.
BACKGROUND: The purpose of this study was to determine: (1) whether stable heart failurepatients with reduced ejection fraction (HFrEF) have elevated extravascular lung water (EVLW) when compared with healthy control subjects; and (2) the effect of acute β2-adrenergic receptor (β2AR) agonist inhalation on lung fluid balance. METHODS: Twenty-two stable HFrEF patients and 18 age- and gender-matched healthy subjects were studied. Lung diffusing capacity for carbon monoxide (DLCO), alveolar-capillary membrane conductance (DmCO), pulmonary capillary blood volume (Vc) (via re-breathe) and lung tissue volume (Vtis) (via computed tomography) were assessed before and within 30 minutes after administration of nebulized albuterol. EVLW was derived as Vtis - Vc. RESULTS: Before administration of albuterol, Vtis and EVLW were higher in HFrEF vs control (998 ± 200 vs 884 ± 123 ml, p = 0.041; and 943 ± 202 vs 802 ± 133 ml, p = 0.015, respectively). Albuteroldecreased Vtis and EVLW in HFrEF patients (-4.6 ± 7.8%, p = 0.010; -4.6 ± 8.8%, p = 0.018) and control subjects (-2.8 ± 4.9%, p = 0.029; -3.0 ± 5.7%, p = 0.045). There was an inverse relationship between pre-albuterol values and pre- to post-albuterol change for EVLW (r2 = -0.264, p = 0.015) and DmCO (r2 = -0.343, p = 0.004) in HFrEF only. CONCLUSION: Lung fluid is elevated in stable HFrEF patients relative to healthy subjects. Stimulation of β2ARs may cause fluid removal in HFrEF, especially in patients with greater evidence of increased lung water at baseline.
Authors: Meshell D Johnson; Hui-Fang Bao; My N Helms; Xi-Juan Chen; Zac Tigue; Lucky Jain; Leland G Dobbs; Douglas C Eaton Journal: Proc Natl Acad Sci U S A Date: 2006-03-20 Impact factor: 11.205
Authors: Massimo F Piepoli; Agnieszka Kaczmarek; Darrel P Francis; L Ceri Davies; Mathias Rauchhaus; Ewa A Jankowska; Stefan D Anker; Alessandro Capucci; Waldemar Banasiak; Piotr Ponikowski Journal: Circulation Date: 2006-07-03 Impact factor: 29.690
Authors: Yogesh N V Reddy; Masaru Obokata; Katlyn E Koepp; Alexander C Egbe; Brandon Wiley; Barry A Borlaug Journal: Circ Res Date: 2019-01-18 Impact factor: 17.367
Authors: C Charles Jain; Juerg Tschirren; Yogesh N V Reddy; Vojtech Melenovsky; Margaret Redfield; Barry A Borlaug Journal: JACC Cardiovasc Imaging Date: 2021-11-17
Authors: Matthias Peter Hilty; Daniel Peter Franzen; Christophe Wyss; Patric Biaggi; Marco Maggiorini Journal: Ann Intensive Care Date: 2017-08-22 Impact factor: 6.925
Authors: Lucie Šedová; Ivana Buková; Pavla Bažantová; Silvia Petrezsélyová; Jan Prochazka; Elena Školníková; Dagmar Zudová; Josef Včelák; Pavol Makovický; Běla Bendlová; Ondřej Šeda; Radislav Sedlacek Journal: Int J Mol Sci Date: 2021-04-07 Impact factor: 5.923